Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

coronavirus main protease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (22) Virus Protease (14) Amyloid-β (2) Apoptosis (2) Cathepsin (3) CDK (1) COX (1) Drug Intermediate (1) PROTACs (3) Reactive Oxygen Species (ROS) (2) Sirtuin (1)
By Research Areas:	Infection (22) Inflammation/Immunology (2) Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Targets Recommended: SARS-CoV Virus Protease HCV Protease HIV Protease Protease Activated Receptor (PAR) ClpP TMPRSS6 Calpain Serpin Enteropeptidase Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156654

Ibuzatrelvir 1 Publications Verification PF-07817883	SARS-CoV Virus Protease	Infection
Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M ^pro and 3CL ^pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .

HY-156655A

Olgotrelvir sodium STI-1558 sodium	SARS-CoV Cathepsin Virus Protease	Infection
Olgotrelvir (STI-1558) sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells .

HY-156655

Olgotrelvir STI-1558	SARS-CoV Virus Protease Cathepsin	Infection
Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells .

HY-W004812

BOC-(1R,3S)-3-aminocyclopentane carboxylic acid (1S,3S)-3-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid	Drug Intermediate SARS-CoV	Infection
BOC-(1R,3S)-3-aminocyclopentane carboxylic acid ((1S,3S)-3-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid) is a conformationally constrained peptide building block and a key component of SARS-CoV-2 main protease (Mpro) inhibitors. When incorporated into macrocyclic peptides, BOC-(1R,3S)-3-aminocyclopentane carboxylic acid not only helps generate high-affinity Mpro inhibitors by preorganizing the secondary structure of peptides, but also exerts sequence-dependent functional inhibition on the hydrolytic activity of Mpro. BOC-(1R,3S)-3-aminocyclopentane carboxylic is widely used in COVID-19-related research .

HY-N8671

Withanoside V	Amyloid-β Apoptosis Reactive Oxygen Species (ROS) SARS-CoV	Infection Neurological Disease
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 M_pro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .

HY-172553

AS-0017445	Virus Protease SARS-CoV	Infection
AS-0017445 is an inhibitor targeting the main protease of both the current *coronavirus* and the virus that caused the Middle East Respiratory Syndrome (MERS) outbreak. AS-0017445 inhibits the viral protein processing in host cells and thus prevents viral replication .

HY-N8693

Withanoside IV	COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV	Infection Neurological Disease
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .

HY-178480

SARS-CoV-2 Mpro-IN-49	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-49 (Compound 22e) is a potent SARS-CoV-2 main protease (M ^pro) inhibitor (IC₅₀=0.087 μM). SARS-CoV-2 Mpro-IN-49 is promising for research of SARS-CoV-2 and coronavirus .

HY-176229

Mpro/Cathepsin L-IN-2	SARS-CoV Cathepsin Virus Protease	Infection
Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 main protease (M ^pro, pIC₅₀=8.61) and human cathepsin L (hCTSL, pIC₅₀=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections .

HY-162464

MPD2	PROTACs SARS-CoV	Infection
MPD2 is a Cereblon-binding ligand-based PROTAC that degrades MPro, the main protease of SARS-CoV-2. MPD2 effectively reduced MPro protein levels in 293T cells in a time-dependent manner (DC₅₀=296 nM). MPD2 exhibited potent antiviral activity against multiple SARS-CoV-2 strains and had enhanced potency against Nirmatrelvir (HY-138687) resistant strains. MPD2 provides a new direction for antiviral drug development against SARS-CoV-2 and other emerging coronavirus pathogens (Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker (HY-W275882)；Red: SARS-CoV-2 MPro Inhibitor MP18 (HY-158763)) .

HY-171781

FL-166	SARS-CoV Virus Protease	Infection
FL-166 is a SARS coronavirus main protease (Mpro) inhibitor (K_i: 40 nM). FL-166 exerts its inhibitory effect by targeting a cluster of serine residues near the active site of the protease. FL-166 can be used in the study of SARS-CoV .

HY-N15268

Koenine	SARS-CoV Virus Protease	Infection
Koenine is a carbazole alkaloid. It is predicted that Koenine has strong binding affinity and inhibitory ability to SARS-CoV-2 main protease (M ^pro), which can be used in the research of anti-novel coronavirus drugs .

HY-155843

CDK9-IN-25	CDK SARS-CoV Virus Protease	Infection
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC₅₀: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC₅₀: 63.28 μM) .

HY-W348072

SARS-CoV-2-IN-59	SARS-CoV	Infection
SARS-CoV-2-IN-59 (compound E07), an imidazoline derivative, is a non-peptide small molecule inhibitor of SARS-CoV-2 that targets the main protease (Mpro) of the coronavirus. SARS-CoV-2-IN-59 has a strong interaction with residues on Mpro (Met 165, Gln 166, Met 165, His 41, Gln 189) .

HY-172214

AB-343	SARS-CoV Virus Protease	Infection
AB-343 is a selective covalent inhibitor of SARS-CoV-2 Mpro, with an IC₅₀ of 8 nM and a K_i of 2.8 nM. AB-343 can effectively inhibit the main proteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .

HY-172960

SARS-CoV-2 Mpro-IN-44	SARS-CoV Virus Protease	Infection Inflammation/Immunology
SARS-CoV-2 Mpro-IN-44 (Compound 25) is a broad-spectrum coronavirus main protease (Mpro) inhibitor. SARS-CoV-2 Mpro-IN-44 has inhibitory activity against a variety of high-risk coronaviruses (including SARS-CoV-2 and PEDV, etc.) (IC₅₀: < 0.6 μM). SARS-CoV-2 Mpro-IN-44 achieves broad-spectrum inhibition of coronaviruses by enhancing the interaction with the conserved sites of Mpro. SARS-CoV-2 Mpro-IN-44 can be used for anti-coronavirus drug development .

HY-172965

SARS-CoV-2 Mpro-IN-43	SARS-CoV Virus Protease	Infection Inflammation/Immunology
SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus main protease (Mpro) inhibitor (IC₅₀: 72 μM). SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC₅₀ values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research .

HY-181870

PROTAC SARS-CoV-2 Mpro degrader-8	PROTACs SARS-CoV	Infection
PROTAC SARS-CoV-2 Mpro degrader-8 is an antiviral PROTAC degrader targeting the SARS-CoV-2 main protease (Mpro), with weak direct binding affinity to Mpro (K_d=80.5 μM). PROTAC SARS-CoV-2 Mpro degrader-8 exhibits broad-spectrum antiviral activity against SARS-CoV-2 and the human endemic coronavirus HCoV-OC43. It can be used for research on coronavirus infections .

HY-181983

VPC285785	SARS-CoV	Infection
VPC285785 is an orally active SARS-CoV-2 main protease inhibitor with an IC₅₀ of 0.8 μM and a K_d of 2.7 μM. VPC285785 functionally inhibits the viral main protease-mediated processing of viral polyprotein precursors required for viral replication. VPC285785 reduces viral loads in the liver, brain and spleen tissues of MHV-infected mice. VPC285785 is applicable to the research of coronavirus infections .

HY-181192

PROTAC SARS-CoV-2 Mpro degrader-6	PROTACs SARS-CoV Virus Protease	Infection
PROTAC SARS-CoV-2 Mpro degrader-6 is a PROTACs degrader targeting the SARS-CoV-2 main protease (M ^pro). PROTAC SARS-CoV-2 Mpro degrader-6 effectively induces the degradation of M ^pro and increases K48-linked polyubiquitination of M ^pro in HEK293 cells. PROTAC SARS-CoV-2 Mpro degrader-6 can be used in studies related to coronavirus disease 2019 (COVID-19) .

HY-183266

SR-A-174	SARS-CoV Virus Protease	Infection
SR-A-174 is a SARS-CoV-2 M ^Pro inhibitor with an IC₅₀ of 0.060 μM. SR-A-174 has limited cell permeability and exhibits low activity in cells expressing M ^Pro-eGFP, with a cellular IC₅₀ > 10 μM. SR-A-174 can be used in COVID-19-related research .

HY-183956

GC813	SARS-CoV	Infection
GC813 is a MERS-CoV 3CL protease (3CL_pro) and MERS-CoV main protease (M_pro) inhibitor. GC813 can be used for the research of middle east respiratory syndrome .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8671

Withanoside V	Structural Classification Withania somnifera Solanaceae Plants Steroids Source Classification	Amyloid-β Apoptosis Reactive Oxygen Species (ROS) SARS-CoV
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 M_pro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .

HY-N8693

Withanoside IV	Structural Classification Withania somnifera Solanaceae Plants Steroids Source Classification	COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .

HY-N15268

Koenine	Alkaloids Pyrrole Alkaloids Rutaceae Murraya koenigii (L.) Spreng Plants Source Classification	SARS-CoV Virus Protease
Koenine is a carbazole alkaloid. It is predicted that Koenine has strong binding affinity and inhibitory ability to SARS-CoV-2 main protease (M ^pro), which can be used in the research of anti-novel coronavirus drugs .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

coronavirus main protease

Inhibitors & Agonists

NaturalProducts

Natural
Products